Evidence map›Paper›PMID 28791529›Full record

ReviewCurrent hypertension reports2017

Effects of RAAS Inhibitors in Patients with Kidney Disease.

Fan Zhang, Hong Liu, Di Liu, Yexin Liu, Huiqiong Li, Xia Tan, Fuyou Liu, Youming Peng, Hongqing Zhang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current hypertension reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 4 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 4 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Observational
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Fan ZhangDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Renal Research Institute of Central South University, Key Lab of Kidney Disease and Blood Purification in Hunan, Changsha, China.
Hong LiuDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Renal Research Institute of Central South University, Key Lab of Kidney Disease and Blood Purification in Hunan, Changsha, China. liuh0618@163.com.
Di LiuDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Renal Research Institute of Central South University, Key Lab of Kidney Disease and Blood Purification in Hunan, Changsha, China.
Yexin LiuDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Renal Research Institute of Central South University, Key Lab of Kidney Disease and Blood Purification in Hunan, Changsha, China.
Huiqiong LiDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Renal Research Institute of Central South University, Key Lab of Kidney Disease and Blood Purification in Hunan, Changsha, China.
Xia TanDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Renal Research Institute of Central South University, Key Lab of Kidney Disease and Blood Purification in Hunan, Changsha, China.
Fuyou LiuDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Renal Research Institute of Central South University, Key Lab of Kidney Disease and Blood Purification in Hunan, Changsha, China.
Youming PengDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Renal Research Institute of Central South University, Key Lab of Kidney Disease and Blood Purification in Hunan, Changsha, China.
Hongqing ZhangDepartment of Nephrology, The Second Xiangya Hospital of Central South University, Renal Research Institute of Central South University, Key Lab of Kidney Disease and Blood Purification in Hunan, Changsha, China.
Second Xiangya Hospital of Central South University · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteinuria and decline of renal function are associated with progression of kidney disease. The Renin Angiotensin Aldosterone System (RAAS) plays an important role in blood pressure regulation, fluid volume, and sodium balance. Overactivity of RAAS contributes to the pathogenesis of a variety of clinical conditions including progress of chronic kidney disease (CKD). This review summarizes the use of RAAS inhibitors as dual therapy or monotherapy in different stages of kidney disease. Experimental and clinical studies have demonstrated RAAS inhibitors prevent proteinuria, kidney fibrosis and slow decline of renal function and thus play a protective role in both early and end stages of kidney disease. While combination use of RAAS inhibitors showed higher efficiency compared with monotherapy, it is also associated with higher incidence of adverse events. Besides ACEI/ARBs, more mechanism research of mineralocorticoid receptor antagonists in kidney disease should be performed.

Indexed as

Renal Insufficiency, ChronicAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsDisease ProgressionHumansHypertensionMedication Therapy ManagementRenin-Angiotensin SystemAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsChronic kidney diseaseProteinuriaRAASRAAS inhibitorsRenin Angiotensin Aldosterone System

Identifiers

PMID28791529
OpenAlexW2743806458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.